EP0785786A1 - Mikrobielle synthese von hiv-proteasehemmer - Google Patents

Mikrobielle synthese von hiv-proteasehemmer

Info

Publication number
EP0785786A1
EP0785786A1 EP95937602A EP95937602A EP0785786A1 EP 0785786 A1 EP0785786 A1 EP 0785786A1 EP 95937602 A EP95937602 A EP 95937602A EP 95937602 A EP95937602 A EP 95937602A EP 0785786 A1 EP0785786 A1 EP 0785786A1
Authority
EP
European Patent Office
Prior art keywords
hiv
compound
aids
treatment
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95937602A
Other languages
English (en)
French (fr)
Other versions
EP0785786A4 (de
Inventor
Ali Shafiee
Shieh-Shung T. Chen
Byron H. Arison
Randall R. Miller
George M. Garrity
Brian Heimbuch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0785786A1 publication Critical patent/EP0785786A1/de
Publication of EP0785786A4 publication Critical patent/EP0785786A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention is concerned with a novel process for synthesizing compounds that inhibit the protease encoded by human immunodeficiency virus (HIV), and in particular certain oligopeptide analogs, such as derivatives of Compound J in the Examples below. These compounds are of value in the prevention of infection by HIV, the treatment of infection by HIV and the treatment of the resulting acquired immune deficiency syndrome (AIDS). These compounds are also useful for inhibiting renin and other proteases.
  • HIV human immunodeficiency virus
  • oligopeptide analogs such as derivatives of Compound J in the Examples below.
  • AIDS acquired immune deficiency syndrome
  • HIV HIV
  • LAV low-density virus
  • HTLV-III HTLV-III
  • ARV advanced immune deficiency syndrome
  • a common feature of retrovirus replication is the extensive post-translational processing of precursor polyproteins by a viral ly encoded protease to generate mature viral proteins required for virus assembly and function. Inhibition of this processing prevents the production of normally infectious virus. For example, Kohl, N. E. ct ai, Proc. Nat'l Acacl.
  • the nucleotide sequence of HIV shows the presence of a roj gene in one open reading frame [Ratner, L. ct ai. Nature. 313, 277 ( 1985) . Amino acid sequence homology provides evidence that the go! sequence encodes reverse transcriptase, an endonuclease and an HIV protease [Toh, H. et ai, EMBO J., 4, 1267 ( 1985); Power, M. D. ct ai. /12492 PC17US95/13628
  • Applicants have identified and synthesized a variety of derivatives of Compound J, by incubating Compound J with a selected microbial system, MA7065.
  • the new compounds are active and potent inhibitors of HIV protease.
  • Biotransformation products of a fermentation with culture MA7065 are potent HIV protease inhibitors. These products are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
  • a method for synthesizing biotransformation products of the Compound J having the structure:
  • a preferred compound is compound A. Also covered are the purified biotransformation products of this method, as well as the corresponding chemical compounds.
  • Streptomyces sp. MA7065 AS2023, CRA-3-4 ATCC .
  • This culture produces analogs of Compound J, an inhibitor of HIV protease, by biotransformation. Observations of growth, general cultural characteristics and carbon source utilization were made in accordance with the methods of Shirling and Gottleib (Internal. J. System. Bacterial. 16, 313 - 340). Chemical composition of the cells was determined using the methods of Lechevalier and Lechevalier (in Actinomycete Taxonomy, A. Dietz and D. W. Thayer, Ed., Society for Industrial Microbiology, 1980).
  • Source - Culture MA7065 was isolated from a soil sample collected in a fire-break beside a fallow field that had undergone controlled burning 48h prior to sampling. The field was located in Santa Rosa Park, Guanacaste PR, Costa Rica.
  • Chemotaxonomic characteristics The peptidoglycan of MA7065 contains LL-diaminopimelic acid. Major whole cell fatty acids are listed in Table 1.
  • Micromorphology - Aerial mycelia arise from substrate mycelia in a verticilate fashion.
  • the aerial mycelium terminates in chains of spores that occur as short, loosely coiled spirals. Sporulation occurs on yeast extract malt extract agar, inorganic salts-starch agar, oatmeal, glycerol asparagine agar, Czapek's agar and tap-water agar.
  • the aerial spore mass coalesces on inorganic salts-starch agar.
  • MA7065 has a type I cejl wall. Mo ⁇ hological studies reveal that the culture produces short chains of spores on spiral sporophores, arranged in pseudoverticils which arise from the aerial mycelium. These are characteristics that are typical for some strains of Streptomyces spp. A comparison of the phenotypic data for MA7065 with that of the validly published species of Streptomyces in the taxonomic literature shows that this strain bears some resemblance to Streptomyces albo riseolus, Stmy. lydicus, Stmy. parvulus and Stmy. rochcii. Of these species, only Stmy.
  • MA7065 is a novel strain of Stmy. lydicus.
  • the preferred sources of nitrogen are yeast extract, meat extract, peptone, gluten meal, cottonseed meal, soybean meal and other vegetable meals (partially or totally defatted), casein hydrolysates, soybean hydrolysates, and yeast hydrolysates, co steep liquor, dried yeast, wheat germ, feather meal, peanut powder, distiller's solubles, etc., as well as inorganic and organic nitrogen compounds such as ammonium salts (e.g., ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea, amino acids, and the like.
  • ammonium salts e.g., ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.
  • urea amino acids, and the like.
  • the carbon and nitrogen sources need not be used in their pure form, because less pure materials which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use.
  • the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, cobalt salts, and the like.
  • a defoaming agent such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone may be added.
  • the compounds of this invention can also be obtained by synthetic organic procedures by a skilled artisan.
  • a shaking or surface culture in a flask or bottle is employed.
  • the vegetative forms of the organism for inoculation in the production tanks in order to avoid growth lag in the process of production. Accordingly, it is desirable first to produce a vegetative inoculum of the organism by inoculating a relatively small quantity of culture medium with spores or mycelia of the organism produced in a "slant" and culturing said inoculated medium, also called the "seed medium", and then to transfer the cultured vegetative inoculum aseptically to large tanks.
  • the fermentation medium, in which the inoculum is produced is generally autoclaved to sterilize the medium prior to inoculation.
  • Agitation and aeration of the culture mixture may be accomplished in a variety of ways. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermentor, by various pumping equipment or by the passage of sterile air through the medium. Aeration may be effected by passing sterile air through the fermentation mixture.
  • the fermentation is usually conducted at a temperature between about 20°C and 40°C, preferably 25-35°C, for a period of about 10 hours to 64 hours, which may be varied according to fermentation conditions and scales.
  • the production cultures are incubated for about 48 hours at 28°C on a rotary shaker operating at 220 ⁇ m, wherein the pH of the fermentation medium is maintained at 4.85 to harvest.
  • Preferred culturing/production media for carrying out the fermentation include the following media:
  • Seed medium consisted of: 0.1 % dextrose; 1 % dextrin; 0.3% beef extract; 0.5% ardamine pH; 0.5% NZ amine type E; 0.005% MgS ⁇ 4-7H2 ⁇ , and 0.037% K2HPO4 with pH adjusted to 7.1 with 0.05% CaC03.
  • Biotransformation medium contained: 2% glucose; 0.5% soya meal; 0.5% yeast extract; 0.5% NaCl; 0.98% MES with pH adjusted to 7.0. The products can be recovered from the culture medium by conventional means which are commonly used for the recovery of other known substances.
  • the substances produced are obtained by filtering or centrifuging the cultured broth, by a conventional method such as concentration under reduced pressure, lyophilization, extraction with a conventional solvent, such as methylene chloride or methanol and the like, pH adjustment, treatment with a conventional resin (e.g., anion or cation exchange resin, non-ionic adso ⁇ tion resin, etc.), treatment with a conventional adsorbent (e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), crystal ⁇ lization, recrystallization, and the like.
  • a conventional resin e.g., anion or cation exchange resin, non-ionic adso ⁇ tion resin, etc.
  • a conventional adsorbent e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.
  • the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds.
  • the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV protease, e.g., by competitive inhibition.
  • the compounds of this invention are commercial products to be sold for these pu ⁇ oses.
  • the compounds of the present invention are useful in the inhibition of HIV protease, the prevention or treatment of infection by the human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as AIDS.
  • HIV human immunodeficiency virus
  • Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV.
  • the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
  • the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
  • a method of treating and a pharmaceutical composition for treating HIV infection and AIDS involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutical ly effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
  • compositions may be in the form of orally-administrable suspensions or tablets; nasal sprays; sterile injectable preparations, for example, as sterile injectable aqueous or oleagenous suspensions or suppositories.
  • these compositions When administered orally as a suspension, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweetners/flavoring agents known in the art.
  • these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
  • these compositions When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, abso ⁇ tion promoters to enhance bioavailability, fluorocarbons. and/or other solubilizing or dispersing agents known in the art.
  • the injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally- acceptable diluents or solvents, such as mannitol, 1 ,3-butanediol. water. Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • suitable non-toxic, parenterally- acceptable diluents or solvents such as mannitol, 1 ,3-butanediol. water.
  • Ringer's solution or isotonic sodium chloride solution or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • compositions When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non- irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
  • a suitable non- irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
  • Dosage levels of the order of 0.02 to 5.0 or 10.0 grams- per-day are useful in the treatment or prevention of the above-indicated conditions, with oral doses two-to-five times higher.
  • infection by HIV is effectively treated by the administration of from 1.0 to 50 milligrams of the compound per kilogram of body weight from one to four times per day.
  • dosages of 100- 400 mg every six hours are administered orally to each patient.
  • the present invention is also directed to combinations of the HIV protease inhibitory compounds with one or more agents useful in the treatment of AIDS.
  • the compounds of this invention may be effectively administered, whether at periods of pre- exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art.
  • Ganciclovir (Palo Alto, CA) peripheral CMV retinitis
  • Virazole Viratek/ICN asymptomatic HIV Ribavirin (Costa Mesa, CA) positive, LAS, ARC
  • Methionine- TNI Pharmaceutical AIDS, ARC Enkephalin (Chicago, IL)
  • Granulocyte Amgen AIDS in combination Colony Stimulating (Thousand Oaks, CA) w/AZT Factor
  • TNF S. San Francisco, w/gamma Interferon CA
  • Isethionate (IM & IV) (Rosemont, IL)
  • Compound B is 6-chloro-4-(S)-cyclopropyl-3,4-dihydro-4-((2- pyridyl)ethynyl)quinazolin-2( 1 H)-one;
  • Compound C is(-) 6-chloro-4(S)-trifluoromethyl- l ,2-dihydro-4(H)-3, l - benzoxazin-2-one; nevirapine is 1 1 -cyclopropy 1-5, 1 1 -dihydro-4-methy 1- 6 /-dipyrido[3,2- ?:2',3'- ⁇ ?][ l ,4]diazepin-6-one.
  • Compounds B and C are synthesized by the methods of EP 0,569,083, herein inco ⁇ orated by reference for this pu ⁇ ose. Nevirapine is synthesized by Klunder, J. M. et ai, J. Med. Chem.
  • Preferred combinations are simultaneous or alternating treatments of an inhibitor of HIV protease and a non-nucleoside inhibitor of HIV reverse transcriptase.
  • An optional third component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, ddC or ddl.
  • a preferred inhibitor of HIV protease is Compound A.
  • Preferred non-nucleoside inhibitors of HIV reverse transcriptase include Compound B, Compound C or nevirapine. These combinations may have synergistic effects on limiting the spread of HIV. Preferred combinations include the following ( 1 ) Compound A, with a preferred non-nucleoside inhibitor of HIV reverse transcriptase, and, optionally, AZT or ddl or ddC; (2) Compound A, and any of AZT or ddl or ddC.
  • the reaction was quenched with 160 ⁇ l of 5% phosphoric acid.
  • Products of the reaction were separated by HPLC (VYDAC wide pore 5 cm C- 18 reverse phase, acetonitrile gradient, 0.1 % phosphoric acid).
  • the extent of inhibition of the reaction was determined as IC50 from the peak heights of the products.
  • Inhibition of the spread of HIV in cell culture was measured according to Nunberg, J. H. et al., J. Virol. 65, 4887 (1991 ).
  • MT-4 T-lymphoid cells were infected with HIV- 1 (wild- type, unless otherwise indicated) by using a predetermined inoculum, and cultures were incubated for 24 h. At this time, ⁇ 1 % of the cells were positive by indirect immunofluorescence. Cells were then extensively washed and distributed into 96-well culture dishes. Serial twofold dilutions of inhibitor were added to the wells, and cultures were continued for 3 additional days. At 4 days postinfection, 100% of the cells in control cultures were infected. HIV-1 p24 accumulation was directly correlated with virus spread.
  • the cell culture inhibitory concentration was defined as the inhibitor concentration in nanomoles/liter which reduced the spread of infection by at least 95%, or CIC95-
  • MT cells were infected at Day 0 at a concentration of 250,000 per ml with a 1 : 1000 dilution of HIV-1 strain Illb stock (final 125 pg p24/ml; sufficient to yield ⁇ 1 % infected cells on day 1 and 25- 100% on day 4).
  • Cells were infected and grown in the following medium: RPMI 1640 (Whittaker BioProducts), 10% inactivated fetal bovine serum, 4 mM glutamine (Gibco Labs) and 1 : 100 Penicillin- Streptomycin (Gibco Labs).
  • the mixture was incubated overnight at 37°C in 5% C02 atmosphere.
  • the settled cells are resuspended and 125 ⁇ l harvested into a separate microtiter plate.
  • the supernatant is assayed for HIV p24 antigen.
  • the concentration of HIV p24 antigen is measured by an enzyme immunoassay, described as follows. Aliquots of p24 antigen to be measured are added to microwells coated with a monoclonal antibody specific for HIV core antigen. The microwells are washed at this point, and at other appropriate steps that follow. Biotinylated HIV-specific antibody is then added, followed by conjugated streptavidin- horseradish peroxidase. A color reaction occurs from the added hydrogen peroxide and tetramethylbenzidine substrate. Color intensity is proportional to the concentration of HIV p24 antigen.
  • fractional inhibitory concentration ratios are calculated according to Elion, et ai, J. Biol. Chem., 208, All ( 1954).
  • the minimum sum of FICS which is the maximum synergy, is determined for various pairwise combinations. The smaller the number, the greater the synergy.
  • A. Culture Preparation Culture MA7065 was grown in seed and biotransformation media, respectively.
  • Seed medium (KE medium) consisted of: 0.1 % dextrose; 1 % dextrin; 0.3% beef extract; 0.5% ardamine pH; 0.5% NZ amine type E; 0.005% MgS ⁇ 4 « 7H2 ⁇ , and 0.037% K2HPO4 with pH adjusted to 7.1 with 0.05% CaC03.
  • Biotransformation medium contained: 2% glucose; 0.5% soya meal; 0.5% yeast extract; 0.5% NaCl: 0.98% MES with pH adjusted to 7.0.
  • MA7065 was grown in KE seed medium. After overnight incubation at 27°C with gyratory shake (220 ⁇ m) two milliliters of each culture was transferred into 250 ml baffled flasks containing 50 ml of soy-glucose bioconversion medium. At zero time, 5 mg of
  • HIV-protease inhibitor Compound J
  • the supernatant was recovered and applied on the top of an activated column containing 14% octadecyl support.
  • the column was washed with water and then eluted with a gradient of an aqueous methanol from 20 to 80%.
  • Each eluted fraction was examined by HPLC on an analytical column.
  • This column was developed with a gradient solvent system consisting of reservoir A and B.
  • Reservoir A contained 10% ammonium acetate : 0.1 % formic acid and reservoir B contained 67% acetonitrile : 33% methanol : 0.1 % formic acid.
  • the gradient was run from 30 to 85% solvent B in 30 min.
  • Mass spectra and daughter ion spectra were obtained by LC/MS/MS on a mass spectrometer using the ionspray interface. Samples were analyzed by direct injection in a mobile phase that consisted of 50% CH3CN/50% 10 mM NH4 ⁇ Ac/0.1 % TFA. Positive ion detection was used.
  • the dilution of the test compound was based on nominal weight. In other cases, especially when the weight was less than 250 ⁇ g, the concentration was checked by HPLC using J as standard.
  • the reaction was treated with pyridinium -toluene- sulfonate (241 g, 0.96 mol, 0.16 equiv.) and stirred for 10 minutes (the pH of the mixture after diluting 1 mL sample with an equal volume of water is between 4.3-4.6). Then, 2-methoxypropene ( 1.27 L, 13.24 mol, 2.2 equiv.) was added and reaction was heated to 38-40°C for 2 h. The reaction mixture was cooled to 20°C and partitioned with ethyl acetate ( 12 L) and 5% aqueous NaHC ⁇ 3 (10 L). The mixture was agitated and the layers were separated.
  • the ethyl acetate extract was washed with 5% aqueous NaHC03 (10 L) and water (4 L).
  • the ethyl acetate extract was dried by atmospheric distillation and solvent switched to cyclohexane (total volume of ⁇ 30L).
  • the hot cyclohexane solution was allowed to slowly cool to 25°C to crystallize the product.
  • the resulting slurry was further cooled to 10°C and aged for 1 h.
  • the product was isolated by filtration and the wet cake was washed with cold ( 10°C) cyclohexane (2 X 800 mL).
  • lithium hexamethyldisilazide LiN[(CH3)3Si]2)(2.6 L, 1.38 M, 1.15 equiv.
  • the reaction mixture was stirred at -45 to -40°C for 1 h and then allowed to warm to -25°C over 1 h.
  • the mixture is stirred between -25 to -22°C for 4 h (or until the starting acetonide is 3.0 area %).
  • the mixture was partitioned with ethyl acetate (40 L) and water (3 L). The mixture was agitated and the layers were separated.
  • the HPLC assay yield of 6 in ethyl acetate was 86.5%.
  • the penultimate compound 6 in DMF was directly used in the next step without further purification.
  • the carboxylic acid 8 was suspended in 27 L of EtOAc and 120 mL of DMF in a 72 L 3-neck flask with mechanical stirring under N2 and the suspension was cooled to 2°C. The oxalyl chloride was added, maintaining the temperature between 5 and 8°C.
  • the assay for completion of the acid chloride formation is important because incomplete reaction leads to formation of a bis-tert- butyl oxamide impurity.
  • the reaction mixture was aged at 5°C for 1 h.
  • the resulting slurry was cooled to 0°C and the tert-butylamine was added at such a rate as to keep the internal temperature below 20°C.
  • the mixture was aged at 18°C for an additional 30 min.
  • the precipitated ammonium salts were removed by filtration.
  • the filter cake was washed with 12 L of EtOAc.
  • the combined organic phases were washed with 6 L of a 3% NaHC ⁇ 3 and 2 X 2 L of saturated aq. NaCl.
  • the organic phase was treated with 200 g of Darco G60 carbon and filtered through Solka Flok and the cake was washed with 4 L of EtOAc.
  • the EtOAc solution of 9 was concentrated at 10 mbar to 25% of the original volume. 30 L of 1-propanol were added, and the distillation was continued until a final volume of 20 L was reached.
  • the pyrazine-2-tert-butylcarboxamide 9/1 -propanol solution was placed into the 5 gal autoclave.
  • the catalyst was added and the mixture was hydrogenated at 65°C at 40 psi (3 arm) of H2.
  • reaction was monitored by GC: 30 m Megabore column, from 100°C to 160°C at 10°C/min, hold 5 min, then at
  • HPLC 25 cm Dupont Zorbax RXC8 column with 1.5 mL/min flow and detection at 210 nm, isocratic (98/2) CH3CN/O.I % aqueous H3PO4.
  • CH3CN/I -propanol ratio by lH NMR integration showed that the CH3CN/l -propanol/H2 ⁇ ratio was 26/8/1.6.
  • the concentration in the solution was 72.2 g/ L.
  • the (S)-lO-camphorsu.fonic acid was charged over 30 min in 4 portions at 20°C. The temperature rose to 40°C after the CSA was added. After a few minutes a thick white precipitate formed. The white slurry was heated to 76°C to dissolve all the solids, the slightly brown solution was then allowed to cool to 21 °C over 8 h.
  • the ee of the material was 95% according to the following chiral HPLC assay: an aliquot of 11 (33 mg) was suspended in 4 mL of EtOH and 1 mL of Et3N. Boc2 ⁇ ( 1 1 mg) was added and the reaction mixture was allowed to age for 1 h. The solvent was completely removed in vacua, and the residue was dissolved in ca. 1 mL of EtOAc and filtered through a Pasteur pipet with Si ⁇ 2, using EtOAc as eluent. The evaporated product fractions were redissolved in hexanes at ca. 1 mg/mL.
  • the chiral assay was carried out using the same system as in the previous step.
  • the solution was then concentrated to ca. 10 L at an internal temperature of ⁇ 20°C in a batch-type concentrator under 10 mbar vacuum.
  • the solvent switch was completed by slowly bleeding in 20 L of EtOAc and reconcentrating to ca 10 L.
  • the reaction mixture was washed into an extractor with 60 L of EtOAc.
  • the organic phase was washed with 16 L of 5% aqueous Na2C ⁇ 3 solution, 2 X 10 L Di water and 2 X 6 L of saturated aqueous sodium chloride.
  • the combined aqueous washes were back extracted with 20 L of EtOAc and the organic phase was washed with 2 X 3 L water and 2 X 4 L of saturated aqueous sodium chloride.
  • the combined EtOAc extracts were concentrated under 10 mbar vacuum with an internal temperature of ⁇ 20°C in a 100 L batch-type concentrator to ca. 8 L.
  • the solvent switch to cyclohexane was achieved by slowly bleeding in ca. 20 L of cyclohexane, and reconcentrating to ca. 8 L.
  • To the slurry was added 5 L of cyclohexane and 280 mL of EtOAc and the mixture was heated to reflux, when everything went into solution.
  • the solution was cooled and seed ( 10 g) was added at 58°C.
  • the slurry was cooled to 22°C in 4 h and the product was isolated by filtration after a 1 h age at 22°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95937602A 1994-10-25 1995-10-20 Mikrobielle synthese von hiv-proteasehemmer Withdrawn EP0785786A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32863494A 1994-10-25 1994-10-25
US328634 1994-10-25
PCT/US1995/013628 WO1996012492A1 (en) 1994-10-25 1995-10-20 Microbial synthesis of hiv protease inhibitors

Publications (2)

Publication Number Publication Date
EP0785786A1 true EP0785786A1 (de) 1997-07-30
EP0785786A4 EP0785786A4 (de) 1998-01-28

Family

ID=23281761

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95937602A Withdrawn EP0785786A4 (de) 1994-10-25 1995-10-20 Mikrobielle synthese von hiv-proteasehemmer

Country Status (4)

Country Link
EP (1) EP0785786A4 (de)
JP (1) JPH10507917A (de)
AU (1) AU702122B2 (de)
WO (1) WO1996012492A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612217A (en) * 1994-10-25 1997-03-18 Merck & Co., Inc. Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors
US5763196A (en) * 1996-01-26 1998-06-09 Boehringer Mannheim Corporation Assays using cross-linked polypeptide fragments of β-galactosidase
US5976857A (en) * 1996-01-26 1999-11-02 Boehringer Mannheim Corporation Cross-linked polypeptide fragments of β-galactosidase
JP2863638B2 (ja) * 1996-01-26 1999-03-03 ベーリンガー マンハイム コーポレイション ビスーマレイミド架橋剤
US7569690B2 (en) 2002-09-05 2009-08-04 Toray Fine Chemicals Co., Ltd. Process for producing oxycarbonyl-substituted piperazine derivative
JP2004115510A (ja) * 2002-09-05 2004-04-15 Toray Fine Chemicals Co Ltd ピペラジン誘導体の製造方法
CN101497608B (zh) * 2009-03-05 2011-11-09 中国科学院广州生物医药与健康研究院 一类hiv蛋白酶抑制剂衍生物及其制备方法和在制备抗肿瘤药中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012790A1 (en) * 1994-10-25 1996-05-02 Merck & Co., Inc. Microbial synthesis of hiv protease inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3160560A (en) * 1957-08-23 1964-12-08 Upjohn Co Streptolydigin and production thereof
JPS5774090A (en) * 1980-10-27 1982-05-10 Shionogi & Co Ltd Novel beta-galactosidase inhibitor, gt-2558, its derivative, and production
CA2081970C (en) * 1991-11-08 1997-07-08 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
CA2110827A1 (en) * 1992-12-14 1994-06-15 Maki Nishio Antiviral antibiotic bu-4724v and preparation thereof
NZ265164A (en) * 1993-03-31 1997-09-22 Merck & Co Inc Pharmaceutical composition comprising a pyridinyl-methyl-piperazine derivative and any of azt, ddi or ddc

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012790A1 (en) * 1994-10-25 1996-05-02 Merck & Co., Inc. Microbial synthesis of hiv protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9612492A1 *

Also Published As

Publication number Publication date
AU3966395A (en) 1996-05-15
AU702122B2 (en) 1999-02-11
EP0785786A4 (de) 1998-01-28
JPH10507917A (ja) 1998-08-04
WO1996012492A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
IE913647A1 (en) Hydroxylated inhibitors of hiv reverse transcriptase
US5646148A (en) HIV protease inhibitors useful for the treatment of AIDS
EP0696277A1 (de) Hiv protease inhibitoren für die behandlung von aids
KR20050098928A (ko) 치환된 헤테로사이클
AU702122B2 (en) Microbial synthesis of HIV protease inhibitors
US6395743B1 (en) HIV integrase inhibitors
US5612217A (en) Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors
GB2306476A (en) Hiv integrase inhibitors
US5858737A (en) Conversion of indene to (1S)-amino-(2R)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps
WO1997000966A1 (en) Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps
KR100453301B1 (ko) 1-트리플루오로메틸-4-히드록시-7-피페리디닐-아미노메틸크로만 유도체
US5605819A (en) Quantitative conversion of indene to (1S,2R) indene oxide and (1S,2R)-indandiol by combination of haloperoxidase bioconversion and chemical steps
CA2203273A1 (en) Microbial synthesis of hiv protease inhibitors
JPH0570448A (ja) Ｈｉｖプロテアーゼ阻害剤
CA2203272A1 (en) Microbial synthesis of hiv protease inhibitors
GB2327674A (en) HIV integrase inhibitors
US5871981A (en) Conversion of indene to (1S)-amino-(2R)-indanol free of any steroisomer by combination of fermentation of Rhodococcus sp. ATCC 55805 and chemical steps
US6221899B1 (en) Terpenoid lactone compounds and their production process
US6277860B1 (en) Furopyridine antibacterials
EP0933373B1 (de) Terpenoide Lactonverbindungen und Verfahren zu ihrer Herstellung
WO1998006865A1 (en) Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of monooxygenase bioconversion and chemical steps
EP0432697A2 (de) BU-4146T-Antibiotikum
US5037836A (en) BU-4146T antibiotic
EP0999212A1 (de) Antibakterielle Furopyridine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970526

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RHK1 Main classification (correction)

Ipc: C07D401/06

A4 Supplementary search report drawn up and despatched

Effective date: 19971215

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19981210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020501